Trial reportJournal of inherited metabolic disease2003
Ophthalmic follow-up of patients with tyrosinaemia type I on NTBC.
Trial report in Journal of inherited metabolic disease, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 49 citations in OpenAlex.
- A 3-year randomized therapeutic trial of nitisinone in alkaptonuria.Molecular genetics and metabolism · 2011Trial
- Overview of European Practices for Management of Tyrosinemia Type 1: Towards European Guidelines.Journal of inherited metabolic disease · 2025Review
- Integrated Analysis of Transcriptomics and Metabolomics Unveil the Novel Insight of One-Year-Old Precocious Mechanism in the Chinese Mitten Crab,International journal of molecular sciences · 2023Article
- Article
- Effects of a protein-restricted diet on body weight and serum tyrosine concentrations in patients with alkaptonuria.JIMD reports · 2022Article
- Incidentally Discovered Ochronosis Explaining Decades of Chronic Pain.Federal practitioner : for the health care professionals of the VA, DoD, and PHS · 2020Article
- Long-Term Outcomes and Practical Considerations in the Pharmacological Management of Tyrosinemia Type 1.Paediatric drugs · 2019Review
- Asymptomatic Corneal Keratopathy Secondary to Hypertyrosinaemia Following Low Dose Nitisinone and a Literature Review of Tyrosine Keratopathy in Alkaptonuria.JIMD reports · 2018Article
- Diagnosis and treatment of tyrosinemia type I: a US and Canadian consensus group review and recommendations.Genetics in medicine : official journal of the American College of Medical Genetics · 2017Review
- Fumarylacetoacetate Hydrolase Knock-out Rabbit Model for Hereditary Tyrosinemia Type 1.The Journal of biological chemistry · 2017Article
- Clinical utility of nitisinone for the treatment of hereditary tyrosinemia type-1 (HT-1).The application of clinical genetics · 2017Review
- Osteoarticular cells tolerate short-term exposure to nitisinone-implications in alkaptonuria.Clinical rheumatology · 2016Article
- Metabolic Effects of Increasing Doses of Nitisinone in the Treatment of Alkaptonuria.JIMD reports · 2015Article
- Cross-sectional study of 168 patients with hepatorenal tyrosinaemia and implications for clinical practice.Orphanet journal of rare diseases · 2014Article
- Reversible keratopathy due to hypertyrosinaemia following intermittent low-dose nitisinone in alkaptonuria: a case report.JIMD reports · 2014Article
- Recommendations for the management of tyrosinaemia type 1.Orphanet journal of rare diseases · 2013Review
- Corneal depositions in tyrosinaemia type I during treatment with Nitisinone.BMJ case reports · 2012Article
- Heterogeneity of follow-up procedures in French and Belgian patients with treated hereditary tyrosinemia type 1: results of a questionnaire and proposed guidelines.Journal of inherited metabolic disease · 2012Article
- New management options for end-stage chronic liver disease and acute liver failure: potential for pediatric patients.Paediatric drugs · 2006Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
NTBC has revolutionized the management of tyrosinaemia type I, although animal experiments have shown that long-term administration may produce corneal opacities analogous to those in tyrosinaemia type II. We have assessed the prevalence of ocular side-effects in 11 tyrosinaemia type I patients on NTBC attending the Birmingham Children's Hospital. Despite high plasma tyrosine concentrations in some patients, they did not experience symptoms or signs of ocular toxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.